EU approves contentious Alzheimer’s medication

The European Union on Thursday approved the highly contentious Alzheimer’s medication Kisunla under strict conditions, with the drug’s effectiveness hotly debated by the medical community.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup